A Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency
This research study is studying a possible therapy as a possible treatment for the consequences of Multiple Myeloma with renal insufficiency.
Multiple Myeloma
DRUG: Denosumab Q4W
Percent Change Of sCTX Levels, 2 years
Percent Change In Bone Mineral Density, 2 years|Percent Change In uNTX Levels, 2 years|Subject Incidence Of Hypocalcemia, 2 years|Subject Incidence Of Occurrence Of Documented SRE At 12 Months, 2 years|Subject Incidence Of Adverse Events, 2 years|Percent Change In Bone Turnover Markers, 2 years
This research study is a Phase II clinical trial. This study will assess the safety and tolerability of denosumab in Multiple Myeloma participants, by studying drug interactions with different parts of the body.

The FDA (the U.S. Food and Drug Administration) has not approved Denosumab for this specific disease but it has been approved denosumab for use in other cancers to treat cancer-related bone disease such as prostate and breast cancer.